FDA Grants Early Access#
The U.S. Food and Drug Administration (FDA) has given Revolution Medicines the green light to provide its experimental pill, daraxonrasib, to patients with previously treated pancreatic cancer. This authorization allows patients with serious conditions to access new treatments before they receive full regulatory approval.
What is Daraxonrasib?#
Daraxonrasib is currently being studied for its effectiveness in patients suffering from metastatic pancreatic ductal adenocarcinoma. This type of pancreatic cancer has spread to other areas of the body and is typically challenging to treat, especially after other therapies have been tried.
Promising Results#
In a recent late-stage trial, Revolution reported that daraxonrasib doubled the survival time for pancreatic cancer patients compared to traditional chemotherapy. This positive outcome led to a rise in the company’s stock price following the announcement.
Future Developments#
The pill is also being tested in late-stage trials for non-small cell lung cancer, another serious condition. Additionally, daraxonrasib has received a priority review voucher from the FDA, which is intended to expedite the development of drugs that meet significant medical needs.
Accessing the Treatment#
Revolution Medicines is working to implement the early access program in the U.S. as soon as possible, ensuring that patients can access the treatment safely and fairly. However, it’s important to note that patients and their caregivers cannot apply directly for access; requests must be made through a licensed treating physician.